Our Pipeline
Our allogeneic, off-the-shelf, VST therapy candidates target 12 different devastating viruses to treat or prevent life-threatening viral diseases.
viewOur Platform
Our proprietary platform develops allogeneic, off-the-shelf VSTs designed to restore immunity in patients with T cell deficiencies.
learnOur People
Our founders have a singular vision: to serve patients at risk of the devastating consequences of severe viral infections and diseases.
meet
